A dual acting drug for enhancing radiotherapeutic benefit

增强放射治疗效果的双重作用药物

基本信息

批准号：
8648499
负责人：
Andrew John Norris
金额：
$ 20.92万
依托单位：
BCN BIOSCIENCES, LLC
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-05-19 至 2016-03-18
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8648499
关键词：
Acute Affect Alveolus American Animal Model Animals California Cancer Patient Cell Death Cessation of life Chest Cicatrix Clinical Clinical Data Coughing Data Development Diffuse Dose Drug Kinetics Edema Epithelial Cells Event Fever Fibrosis Foundations Frequencies Future Goals Hematologic Neoplasms Histologic Hodgkin Disease Hour Human In Vitro Incidence Inflammatory Infiltrate Injury Investigational New Drug Application Ionizing radiation Lead Licensing Los Angeles Lung Lymphocyte Malignant Neoplasms Malignant neoplasm of lung Medical center Modality Molecular Mus Nature Neoplasms Normal tissue morphology Patients Pentoxifylline Pharmaceutical Preparations Phase Platelet Inhibitors Pneumonia Protective Agents Pulmonary Fibrosis Radiation Radiation Injuries Radiation Pneumonitis Radiation Protection Radiation Toxicity Radiation induced damage Radiation therapy Radiation-Protective Agents Reaction Regimen Risk Shortness of Breath Structure of parenchyma of lung Symptoms System Therapeutic Time Tissues Toxic effect Toxicology Treatment Protocols United States United States Food and Drug Administration Universities Whole-Body Irradiation Woman Work base cancer radiation therapy cancer therapy cell killing chemotherapy conditioning design drug development experience improved in vivo in vivo Model interstitial irradiation lung injury lung volume macrophage malignant breast neoplasm meetings men neoplastic neoplastic cell novel patient population pre-clinical preclinical study public health relevance pulmonary function response small molecule success tumor tumor xenograft

项目摘要

ABSTRACT: This proposal entitled "A dual acting drug for enhancing radiotherapeutic benefit" is designed to provide proof of concept evidence that the novel compound EWA001 can protect normal lung tissue from radiation-induced damage within an in vivo model without appreciably protecting neoplastic tissue. The protection of radiation induced lung toxicity from ionizing radiation and in particular, radiation induced pneumonitis and fibrosis, is an unmet need that may benefit thousands of patients considering that more than two thirds will receive radiation therapy during the course of their treatment for cancer with such complications limiting treatment or even resulting in death. In aim 1, we will examine the effect of EWA001 in tumor LLC and human tumor xenografts in vitro and in vivo in conjunction with radiation. In aim 2, we will investigate EWA001's efficacy at protecting against and mitigating radiation induced lung injury in mice. Currently, there is no drug available that would minimize radiation toxicity to normal tissue without interfering with its anti-tumor effect and this data is designed to lead to a successful phase II application where we will further develop the pre-clinical data towards an effective drug to treat radiation induced lung toxicity and pneumonitis.

抽象的：这项题为“增强放射治疗效益的双重作用药物”的提案是旨在提供新型化合物 EWA001 可以保护的概念证明证据在体内模型中，正常肺组织免受辐射引起的损伤，而没有明显的影响保护肿瘤组织。保护辐射引起的肺毒性免受电离辐射，特别是辐射引起的肺炎和纤维化，是一个未得到满足的需求考虑到三分之二以上的患者将接受放射治疗，可能会使数千名患者受益在癌症治疗过程中，此类并发症限制了治疗治疗甚至导致死亡。在目标1中，我们将检查EWA001在肿瘤中的作用 LLC 和人类肿瘤异种移植体外和体内与辐射相结合。在目标 2 中，我们将研究 EWA001 在预防和减轻辐射引起的肺部损伤方面的功效小鼠受伤。目前，还没有任何药物可以最大限度地减少对人体的辐射毒性。正常组织而不干扰其抗肿瘤作用，该数据旨在导致成功的二期应用，我们将进一步开发临床前数据治疗放射引起的肺毒性和肺炎的有效药物。